6mo 1196 Semaglutide
*NOT AVAILABLE to AR, CA, MI, KS
This past June, the US Food and Drug Administration approved Semaglutide, a glucagon-like peptide 1 receptor agonist marketed as Wegovy, for chronic weight management based on results from the four 68-week STEP (Semaglutide Treatment Effect in People with obesity) trials. Now, the findings from a 2-year study presented at the ObesityWeek conference in November suggest that the drug’s weight-loss benefits can be sustained.
Research has shown that at higher doses, Semaglutide could also prevent and treat diabetes, cardiovascular disease, and other related issues such as sleep apnea and osteoarthritis. The reasoning behind this is that patients are not only losing weight but also improving their health. It’s important to note that Semaglutide’s side effects are mild, and you might experience temporary symptoms such as diarrhea, nausea, vomiting, and constipation. These are very management symptoms and tend to occur during the beginning of the course of treatment.